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Abstract
Background & objective: Contralesional 1-Hz repetitive transcranial magnetic stimulation (rTMS) over the right pars
triangularis combined with speech-language therapy (SLT) has shown positive results on the recovery of naming in subacute (5–
45 days) post-stroke aphasia. NORTHSTAR-CA is an extension of the previously reported NORTHSTAR trial to chronic
aphasia (>6 months post-stroke) designed to compare the effectiveness of the same rTMS protocol in both phases.
Methods: Sixty-seven patients with left middle cerebral artery infarcts (28 chronic, 39 subacute) were recruited (01-2014 to
07-2019) and randomized to receive rTMS (N = 34) or sham stimulation (N = 33) with SLT for 10 days. Primary outcome
variables were Z-score changes in naming, semantic ﬂuency and comprehension tests and adverse event frequency. Intentionto-treat analyses tested between-group effects at days 1 and 30 post-treatment. Chronic and subacute results were compared.
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CHUM, Université de Montréal, Montreal, QC, Canada
15
School of Kinesiology and Health Science, York University, Toronto, ON, Canada
17
Department of Special Education and Rehabilitation, Faculty of Human Sciences, University of Cologne, Cologne, Germany
18
Burke Rehabilitation Hospital, White Plains, NY, USA
2

Supplementary material for this article is available on the Neurorehabilitation & Neural Repair website at https://journals.sagepub.com/home/nnr.
Corresponding Author:
Alexander Thiel, MD, Jewish General Hospital, McGill University, 3755 Cote St Catherine Rd, Montreal, QC H3T 1E2 Canada.
E mail: alexander.thiel@mcgill.ca

Zumbansen et al.

307

Results: Adverse events were rare, mild, and did not differ between groups. Language outcomes improved signiﬁcantly in all
groups irrespective of treatment and recovery phase. At 30-day follow-up, there was a signiﬁcant interaction of stimulation and
recovery phase on naming recovery (P <.001). Naming recovery with rTMS was larger in subacute (Mdn = 1.91/IQR = .77) than
chronic patients (Mdn = .15/IQR = 1.68/P = .015). There was no signiﬁcant rTMS effect in the chronic aphasia group.
Conclusions: The addition of rTMS to SLT led to signiﬁcant supplemental gains in naming recovery in the subacute phase only.
While this needs conﬁrmation in larger studies, our results clarify neuromodulatory vs training-induced effects and indicate a
possible window of opportunity for contralesional inhibitory stimulation interventions in post-stroke aphasia.
NORTHSTAR trial registration: https://clinicaltrials.gov/ct2/show/NCT02020421.
Keywords
aphasia, stroke, transcranial magnetic stimulation, speech therapy, language therapy, randomized controlled trial

Introduction
About one-third of all patients with ﬁrst ever stroke suffer
from a language disorder, or aphasia.1–8 About half of these
patients will remain aphasic in the chronic phase after stroke,
especially those with ischemic stroke, who have a low likelihood of recovery.1,3,9 Speech and language therapy (SLT) is
the recommended therapeutic approach to aphasia,10 since it
is effective for language and functional communication improvement.11 However, the affordable intensity of SLT in usual
care settings is likely insufﬁcient to achieve signiﬁcant treatment effects on the language deﬁcit.12
In this context, repetitive transcranial magnetic stimulation
(rTMS) has emerged as a potential supplementary treatment
to potentiate the effectiveness and possibly reduce the duration
of SLT.13 rTMS induces cortical currents of short duration
through rapidly changing magnetic ﬁelds, which can modulate
the excitability and activity of targeted cortical regions. Lowfrequency (1-Hz) rTMS has been associated with downregulation of cortical activity.14 This modality has been used in
post-stroke aphasia to limit the recruitment of compensatory
cerebral networks of the right (unaffected) hemisphere in order
to favor intrahemispheric compensation, which usually is associated with better recovery of certain language functions.15,16
Low-frequency rTMS may be most effective in the subacute
phase when there is a chance to prevent the formation of
maladaptive networks. However, modulating those networks in
the chronic phase may also be possible and beneﬁcial.
Meta-analyses of a few small randomized controlled
trials (RCTs) have reported signiﬁcant effects of rTMS on
aphasia both in subacute and chronic stroke.17,18 As recently pointed out,17 there is a disproportion between the
few original experimental studies on rTMS for aphasia
compared to the number of reviews of the literature, which
all conclude that more multicenter RCTs, with larger
populations and homogenous intervention protocols are
required.
We recently published the results of an international and
multilingual sham-controlled blinded prospective proof-ofconcept trial called NORTHSTAR (NOn-invasive Repeated

Therapeutic STimulation for Aphasia Recovery), designed to
directly compare the effectiveness of rTMS vs tDCS and sham
stimulation in subacute post-stroke aphasia (<45 days). We
conﬁrmed a medium to large positive effect of 1-Hz rTMS
targeting the right pars triangularis on the recovery of naming
performance compared to sham stimulation.19 Here, we report
the results of NORTHSTAR in chronic aphasia (NORTHSTARCA), where the same rTMS protocol was tested in patients at 6
months or more after a ﬁrst ever ischemic stroke. This extension
of the NORTHSTAR study protocol to patients with chronic
aphasia allows for the ﬁrst direct comparison of the same
treatment regime in different phases of aphasia recovery and
thus disentangles timing-speciﬁc training related effects of SLT
from neuromodulatory effects of rTMS.

Methods
Trial Design
This extension of the NORTHSTAR trial in chronic aphasia
was a two-armed sham-controlled blinded prospective proofof-concept study, where patients were randomized to sham or
rTMS treatment (allocation ratio 1:1). For 10 sessions over 2
weeks, patients received 45 minutes of individualized SLT by
a certiﬁed therapist according to best-practice guidelines.10
SLT started immediately following real/sham rTMS. Outcome measures were assessed one and 30 days following the
last therapy session.

Study Settings
NORTHSTAR in subacute aphasia took place from January
2014 to March 2018 in Canada at the Jewish General Hospital
(JGH, Montreal), CHUM-Hôpital Notre-Dame (Montreal)
and Toronto Rehabilitation Hospital (Toronto); in the United
States at Burke Rehabilitation Hospital (White Plains); and in
Germany at the Rehabilitation Hospital RehaNova (Cologne).
Subacute participants were recruited in the stroke units at each
site. The extension to chronic aphasia started in September
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2014 and lasted until July 2019 in Canada at the JGH. Chronic
participants were recruited from the neurology outpatient clinic
of the JGH and from associations of people with aphasia in
Montreal. The trial protocol was approved by the Research
Ethics Boards both at the central coordinating center (JGH) and
each participating site. Institutional Review Board of the
Faculty of Medicine, McGill University (Study approval ID
A05-M47-13A). Patients and their relatives received written
and conversational information about the study. Supplementary pictographic material was used if needed. Procedures were
in accordance with institutional guidelines. Written informed
consent was obtained from all participants before the study.

Patient Population
Eligible participants for NORTHSTAR were right-handed adults
aged 18–90 years, with English, French, or German as language
of daily use, having sustained a single left middle cerebral artery
ischemic stroke resulting in aphasia, and whose performance
was below the lower limit of the norm on at least one of the
primary outcome measures (see below) at baseline. Exclusion
criteria included a previous stroke, a new stroke since the initial
event causing the aphasia, severe comprehension deﬁcit that
might compromise informed consent or understanding of instructions, contraindications to MRI and/or TMS, neurodegenerative or psychiatric disease, epilepsy or EEG-documented
epileptic discharges, severe chronic renal or liver failure, lifethreatening diseases, auditory or visual deﬁcits that could not be
corrected and might have impaired testing.
In this study, post-stroke stages were deﬁned as follows:
acute (<5 days), subacute (5 days–4 mo), and chronic (>4
mo). Chronic patients were recruited 6 months or more after
aphasia onset, whereas subacute patients were included 5 to
45 days after the stroke. Recruitment age-range and subacute
time-window was extended from the initial protocol (age 50–
85, 5–30 days post-stroke) in February 2015 to accelerate
recruitment. Patients with chronic aphasia were recruited at
the JGH, and through advertisements in associations of
people with aphasia in the province of Quebec.
Included patients underwent a T1-weighted MRI. Prior to
analysis and unblinding, 2 raters (AT and AZ) independently
stratiﬁed patients’ scans by infarct location: as affecting the
extended Broca’s area (i.e. the inferior or middle frontal gyri,
anterior insula, premotor cortex and underlying white matter,
and basal ganglia20) or not. For divergent classiﬁcation,
consensus was reached by joint review.
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pulses).21 The coil was oriented to direct the current perpendicular to the target gyrus. For sham stimulation, the coil
was placed over the inter-hemispheric ﬁssure at the vertex and
stimulation was applied with 10% RMT. Stimulation devices
used were the eXimia NBS4, Nexstim Ltd. (JGH, Burke
Rehabilitation Hospital), Magstim R2, Magstim Company Ltd.
(RehaNova) and MagPro X100, MagVenture A/S (Sunnybrook
Hospital and Hôpital Notre-Dame). The stimulation target (right
pars triangularis) was localized using the patient’s T1-weighted
MRI and transferred to the patient’s head using the neuronavigation
system of the TMS device or a modiﬁcation of the surface distance
measurements method.22 SLT sessions were given immediately
following the rTMS procedure to ensure treatment within the
period of maximum rTMS after-effect (about 45 minutes).23

Randomization and Blinding
Participants with chronic aphasia were assigned to study arms
by means of a computer-generated list of random numbers
(non-restricted randomization), concealed from investigators
and research personnel in sequentially numbered, opaque and
sealed envelopes. The technician performing the stimulation
opened a participant’s envelope on the ﬁrst day of treatment,
after the participant had completed all baseline assessments.
For participants with subacute aphasia, computer-generated,
non-restricted randomization by site was performed through an
online system located at the Department of Clinical Epidemiology at the JGH (Montreal). Only the technician performing the
stimulation had access to the randomization information when
logging into the study platform, on the ﬁrst day of treatment.19,24
All patients, therapists, principal investigators and research
personnel assessing clinical outcomes were blinded to the
treatment assignment. Therapists did not attend rTMS sessions.

Primary Outcome Measures and Variables
Primary outcomes were lexical access (in naming and verbal
ﬂuency) and auditory sentence comprehension, core language
functions measured by 3 tests commonly used in English,
French, and German, and comparable across languages: The
Boston Naming Test (BNT, total correct score),25 the semantic verbal ﬂuency task (SF1min),26–28 and the 36-item
Token Test (TT).29 We derived standardized Z-scores based
on the normative data of each test.
The primary outcome variables were the difference in Zscores at days 1 and 30 post-treatment, relative to baseline on
each of these tests.

Intervention
rTMS was applied over the non-affected right hemisphere
(pars triangularis of the right inferior frontal gyrus) using a
70 mm ﬁgure-of-eight coil at 1 Hz for 900 pulses (15 minutes)
at 90% resting motor threshold (RMT). RMT was determined
prior to each treatment session over the right primary motor
area (amplitude of motor evoked potentials >50 μV in 5/10

Secondary Outcome Measures and Variable
Secondary outcome measures were integral measures of
aphasic impairment. In the absence of a single test for aphasic
impairment normalized in all 3 languages, we used approved
language speciﬁc batteries: the Protocole Montréal-Toulouse-86
in French,30 the Western Aphasia Battery (WAB)31 in English,
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Figure 1. NORTHSTAR-CA participant ﬂow diagram.

and the Aachener Aphasie Test in German.32 We derived a
standardized T-score, the Uniﬁed Aphasia Score (UnAS) based
on the normative data available for each battery.19
The secondary outcome variable was the percent difference
of UnAS at days 1 and 30 post-treatment, relative to baseline.

Adverse Events and Serious Adverse Event Outcomes
AE during or ≤1h after session (headache, scalp dysesthesia/
paresthesia at stimulation site, and muscle pain of temporal or
neck muscles) and SAE during or following session (seizures) were documented after each therapy session. Cumulative AE and SAE during 10 days of therapy are reported.

Sample Size Determination
The sample size of the NORTHSTAR chronic extension was
determined similarly to the subacute study.24 In order to
detect a 5% difference between treatment groups at P = .01
with a power of .95 in an ANOVA, assuming a standard
deviation of 4%, 12 patients per group (sham and TMS) were

necessary. Based on our previous stroke recovery studies, we
expected a subject attrition rate of 10%. We thus planned to
recruit 30 patients in total. The study was terminated after
enrollment of 28 subjects because lower than expected recruitment rates would have resulted in further study extension, and we already had more than 12 chronic patients per
group having completed the study.

Analyses of Chronic Data
Data from participants with chronic aphasia were analyzed
similarly to the study in subacute aphasia.19 Only data entry
errors were corrected. Distributions were assessed for normality with Shapiro-Wilks tests. We used parametric tests in
the absence of outliers and when data (or square-root
transformed data) were normally distributed. Means (M)
and standard deviations (SD) are reported. If criteria were not
met for parametric tests, related non-parametric tests were
used, and we report median (Mdn) and interquartile ranges
(IQR). Analyses were performed on SPSS-24.0 (IBM Corp.)
and RStudio.33 The signiﬁcance threshold was P < .05.
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Table 1. Demographic & Baseline Clinical Characteristics of Patients with Chronic Aphasia (NORTHSTAR-CA) Per Intervention Group.

N
Male; Female
English; French
Lesion in Broca’s complex,
N (% participants)
Age, mean (SD)
Months post-stroke at recruitment, median (IQR)
Naming (BNT total correct Z-score), mean (SD)
Verbal ﬂuency (SF1min Z-score), median (IQR)
Comprehension (TT Z-score), mean (SD)
UnAS (0-100), mean (SD)

Sham

rTMS

14
9; 5
4; 10
13 (93%)

14
10; 4
5; 9
13 (93%)

66 (9)
33 (84)
7.34 (3.77)
2.54 (2.47)
9.65 (5.36)
21.7 (18.8)

65 (11)
33 (82)
6.34 (3.14)
2.44 (2.30)
8.14 (3.88)
34.9 (27.0)

Between-group comparison (P-value of t-tests
or median tests, where appropriate)

.761
1.000
.449
1.000
.400
.145

Means (and standard deviations) or medians (and interquartile ranges) are displayed according to the normality of the data distribution.
BNT: Boston Naming Test; SF1min: semantic ﬂuency test (animals in 1 minute); TT: 36-item Token Test; UnAS: uniﬁed aphasia score.

Pre-planned primary analyses in chronic patients were
between-group (rTMS vs. Sham) comparisons according to
the intention-to-treat principle for the primary and secondary variables (i.e. Z-score changes on the BNT,
SF1min, and TT, and percent difference of UnAS at days 1
and 30 post-treatment, relative to baseline). Missing data
were replaced by the mean of each corresponding randomization group.
Secondary analyses in chronic patients were performed
on the whole chronic sample (N = 28), independent of
treatment allocation. We used repeated-measures analyses to
identify signiﬁcant changes in all measures between the 3
different observation time points: baseline, immediately
after treatment (1 day post-treatment), and at follow-up (30
days post-treatment). Missing data of the patient who declined follow-up evaluation (see Figure 1) were replaced
using the Last-Observation-Carried-Forward (LOCF)
method for this analysis.

Analyses of Chronic Versus Subacute Data
We compared the effect of rTMS in the subacute and chronic
phases post-stroke with 2-way ANOVAs (rTMS/sham;
subacute/chronic) for medians, a robust alternative to the
traditional 2-way ANOVA, which was not suited for our data
distributions. We performed the analysis in RStudio33 using
the med2way function available in the WRS2 package.34 The
test statistics for the main effects in med2way are F-distributed; the (heteroscedastic) test for the interaction is chisquare distributed.

Results
Chronic Aphasia Results
Participant Flow. A total of 86 chronic patients were assessed
for eligibility to participate in the study. Thirty-two did not

meet the inclusion criteria. Out of 54 eligible patients, 25
declined to participate and 1 patient living in a nursing home
had no resources to be accompanied to study sessions. The
remaining 28 patients were randomized in the 3 study arms.
Figure 1 displays the participant ﬂow.

Baseline Characteristics
Baseline characteristics were similar across intervention
groups (Table 1). In each group, every patient but one had a
lesion affecting Broca’s complex.20 Individual baseline data
are presented in Supplementary Table 1.

rTMS Versus Sham Comparisons
As shown in Table 2, changes relative to baseline in primary
and secondary outcomes did not differ between treatment
groups in patients with chronic aphasia, neither immediately
after treatment (day 1) nor at follow-up (day 30).

Safety
There was no SAE. AEs were rare and their cumulative
numbers did not differ between groups: one patient in the
sham group reported a headache after sessions #1 and #6, and
one patient in the rTMS group reported dysesthesia (tension
in the right shoulder) after session #8.

Main Effect of Time
Table 3 displays the results of the secondary analyses on the
whole chronic participant sample, irrespective of the treatment (rTMS/sham) group. Repeated-measure comparisons
showed signiﬁcant differences between the 3 observation
time points in all language recovery outcomes. Post-hoc tests
revealed that patients improved signiﬁcantly on most measures during the intervention phase (i.e. from baseline to
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Table 2. Comparison of Language Recovery in Patients with Subacute (NORTHSTAR) and Chronic (NORTHSTAR-CA) Post-Stroke
Aphasia in the rTMS and Sham Stimulation Groups.
Subacute Phase
Post-stroke
(NORTHSTAR)
Change
Relative
to Baseline

Sham
N = 19

rTMS
N = 20

Chronic Phase
Post-stroke
(NORTHSTAR-CA)

Sham Chronic/
Subacute
Comparison

rTMS
Chronic/
Subacute
Comparison

Post-hoc
P value

Sham
N = 14

rTMS
N = 14

P
value

P
value

P
Stimulation
value Main Effect

Phase
Main
Effect

Interaction
Effect

.21 (1.08)
.61 (1.00)

.56 (1.69)
.15 (1.68)

.706
.706

.839
.839

.727
.015*

.406
.571

.170
.004*

.455
<.001*

.17 (1.95)
.17 (.49)

.26 (.71)
.36 (.71)

1.000
.706

.839
.107

.103
.727

.845
.857

.320
.060

.634
.144

.35 (1.75)

.82 (2.10)

.706

.02*

.727

.836

.423

.430

.93 (2.22)

.47 (2.16)

.706

.364

.145

.351

.036*

.735

13.64
(46.60)
6.51
(56.44)

9.39
(25.48)
12.53
(37.41)

.706

.616

.727

.788

.762

.886

.257

.107

.296

.487

.352

.368

Naming (BNT total correct Z-score)
day 1
.73 (.94) .90 (1.19)
day 30
1.02
1.91 (.77) rTMS>Sham
(1.71)
(P = .046)*
Verbal ﬂuency (SF1min Z-score)
day 1
.00 (.20) .00 (.46)
day 30
.73 (1.14) .48 (.75)
Comprehension (TT Z-score)
day 1
1.12
.87 (1.99)
(1.87)
day 30
2.07
1.54
(2.57)
(2.22)
UnAS (percent change)
day 1
9.00
6.85
(19.9)
(17.7)
day 30
15.40
26.25
(63.5)
(28.3)

Stimulation x Phase
(P values of Robust
Median ANOVAs)

Post-treatment changes relative to baseline immediately after treatment (day 1), and at follow-up (day 30).
Medians (and interquartile ranges) are displayed for each subgroup as well as P values of median tests.
Signiﬁcance level =.05.
BNT: Boston Naming Test; SF1min: semantic ﬂuency test (animals in 1 minute); TT: 36-item Token Test; UnAS: uniﬁed aphasia score.
*Identiﬁes P values <.05.

immediately post-treatment), where SLT was provided, and
remained stable during the 1-month follow-up period (day 1
to day 30 post-treatment).

Subacute Aphasia Results
We have reported the detailed results of NORTHSTAR in
subacute aphasia elsewhere.19 Thirty-nine participants received either rTMS (N = 20) or sham stimulation (N = 19).
Naming was signiﬁcantly improved by rTMS at 30 days vs
sham stimulation (χ 2 [1] = 5.867; P = .046; φ = .39, medium–
large effect, Figure 2; Table 2). All other primary results were
non-signiﬁcant. The rTMS effect was driven by the patient
subgroup with intact Broca’s area.19

Comparison of Sham Stimulation in Chronic Versus
Subacute Aphasia
In patients allocated to the sham protocol (receiving only
SLT), there was a signiﬁcantly higher improvement in
comprehension (TT) in subacute compared to chronic patients immediately after the treatment (χ 2 [1] = 7.127; P =
.020; φ=.47, medium–large effect, Table 2). The remaining

language changes did not differ signiﬁcantly between the 2
groups of patients.

Contralesional rTMS Effects in Chronic Versus
Subacute Aphasia
As shown in Table 2, the median 2-way ANOVAs did not
reveal any signiﬁcant effect immediately after the treatment.
However, there was a signiﬁcant main effect of time at
follow-up (day 30) on the recovery of naming and comprehension performance favoring patients in the subacute
post-stroke phase. There was no main effect of stimulation,
but there was a signiﬁcant interaction effect of stimulation
and phase on the changes in naming ability (Figure 2). The
effect of rTMS on naming recovery was signiﬁcantly larger
in subacute than chronic patients (χ 2 [1] = 7.771; P = .015;
φ = .48, medium-large effect).

Discussion
This randomized sham-controlled blinded study is the ﬁrst to
compare the effectiveness of 1 Hz subthreshold rTMS over
the right pars triangularis in chronic vs subacute aphasia. In
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Table 3. Whole Sample (N = 28) Data Across Intervention and Follow-Up Phases in Chronic Patients (NORTHSTAR-CA).
Post-hoc tests: mean difference and [95%
CI], or median and (IQR) where
appropriate, and P-value with Bonferroni
correction

Measures

Pretreatment

Posttreatment
day 1

Posttreatment
day 30

6.84
6.22 (3.54)
6.16 (3.62)
Naming (BNT total
(3.44)
correct Z-score),
mean (SD)
2.44
1.68 (2.90)
2.16 (2.68)
Verbal ﬂuency (SF1min
(2.36)
Z-score), median
(IQR)
Comprehension (TT
8.90
8.27 (5.09)
8.03 (5.08)
Z-score), mean (SD)
(4.66)
UnAS, sqrt-transformed 4.77 (2.40) 5.07 (2.33)
5.10 (2.31)
(0-10), mean (SD)

Repeated measure
comparison (P value of Intervention Phase
ANOVAs or equivalent (Pre- to Postnon-parametric tests) treatment day 1)

Follow-up Phase
(Post-treatment
day 1 to 30)

.004*

.62 (.13, 1.11) .010*

.06 ( .24, .35)
1.000

.014*

.26 (.84) 048*

.00 (.56) 1.000

.017*

.63 ( .10, 1.35) .110 .24 ( .45, .94)
1.000
.30 (.13, .47) <.001* .03 ( .15, .21)
1.000

<.001*

BNT: Boston Naming Test; SF1min: semantic ﬂuency test (animals in 1 minute); TT: 36-item Token Test; UnAS: uniﬁed aphasia score; sqrt: square root; IQR:
interquartile range.
*Identiﬁes P values <.05.

line with the literature,11 we found improvements on language measures during SLT and maintenance of gains at 1month follow-up, with similar to larger effects being observed
in the subacute (vs. chronic) phase. An add-on effect of
rTMS, however, was only present in the subacute phase, with
effect sizes exceeding that of SLT alone. There was no
signiﬁcant rTMS effect in the chronic aphasia group.
This direct comparison may support the hypothesis of a
window of neuroplasticity which renders the brain speciﬁcally susceptible to neuromodulatory intervention relatively
early during the course of recovery.35 Most imaging studies in
post-stroke aphasia concur that a shift of task-induced brain
activation is observed in the ﬁrst weeks after the stroke and
that a normalization of activity patterns occurs after several
months.36–38 It has been shown in combined imaging and
brain stimulation studies, that this natural occurring process
can be modulated with rTMS in the ﬁrst 2–12 weeks and that such
successful modulation correlates with therapy response.14,39 Our
results in subacute aphasia show a medium to large effect of
rTMS, which almost doubles naming recovery compared to SLT
alone.19 This effect size is in line with recent meta-analyses17,18
and supports the potential clinical relevance of rTMS in the early
subacute post-stroke phase.
In contrast, our results in chronic aphasia differ from the
conclusions of meta-analyses17,18 and some previous RCTs
using contralesional 1-Hz rTMS in this post-stroke phase.40–43
Methodological differences point to possible explanations and
open avenues for future research. Some “distributed” intervention protocols (applying brain stimulation 10 to 30 times
per day) or delivering therapy during stimulation40,42 have
resulted in improvements in this population, but it may be very

Figure 2. Improvement in naming at follow-up (day 30) after
speech-language therapy combined with rTMS or sham
stimulation in patients in the subacute or chronic phase. Error bars
represent Interquartile ranges (IQR); * indicates signiﬁcant
differences; n.s., non-signiﬁcant; BNT, Boston Naming Test.
There was a signiﬁcant interaction between stimulation and phase
(P < .001). In subacute patients, naming was signiﬁcantly improved by
rTMS (Mdn = 1.91, IQR = .77) compared to sham stimulation
(Mdn = 1.02, IQR = 1.71, P = .046 φ = .39, medium–large effect).
Chronic patients, however, did not differ between treatment
groups. Naming recovery with rTMS was larger in subacute
(Mdn=1.91/IQR=.77) than chronic patients (Mdn = .15, IQR = 1.68,
P = .015, φ = .48, medium–large effect). There was similar
improvement in chronic and subacute patients allocated to sham
stimulation (i.e.,, speech-language therapy only).
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challenging to implement such high-frequency treatments in
most public health systems. Our protocol was designed to ﬁt
into subacute in-patient rehabilitation care pathways in the
participating countries and was readily transferable to an
outpatient setting for chronic participants.
Another possibility is that a signiﬁcant effect of rTMS in
chronic patients may only appear at later follow-up. In
subacute patients the rTMS effect on naming recovery reached
signiﬁcance 1 month after the end of the treatment. This delay
might be even longer in patients at the chronic stage, where
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improvement can also occur, but at a lower rate. Results of
Barwood et al 43 are consistent with this idea in chronic aphasia.
They reported an absence of signiﬁcant results 1 week after 10
days of rTMS in daily blocks of 20 min (without SLT) but a
signiﬁcant beneﬁcial effect at 2-month follow-up.
Among studies on chronic aphasia, the closest RCTs to our
design are those of Tsai et al.41, where 33 participants received 10 daily stimulation blocks of 10 min followed by 60
min of SLT, and Wang et al.,42 where a group of 15 patients
received 10 daily stimulation blocks of 20 min followed by 20

Figure 3. Lesion overlap maps spatially normalized to MNI-stereotaxic space for subgroups of patients, and lesion volumes in mL (means and
standard deviations). Lesion volumes were not signiﬁcantly different in rTMS and sham groups (main effect: F [1, 54] < .01, P = .99, partial η2
= .00) and there was no statistically signiﬁcant interaction between phases and treatment groups (F [1, 54] = .86, P = .36, partial η2 = .02).
Patients in the chronic phase had signiﬁcantly larger lesions than patients in the subacute phase (main effect: F [1, 54] = 11.97, P < .01, partial η2
= .18). (a) Subacute phase patients in the rTMS group (M = 39.2, SD = 37.1). (b) Subacute phase patients in the sham group (M = 51.3, SD =
39.9). (c) Chronic phase patients in the rTMS group (M = 98.8, SD = 65.3). (d) Chronic phase patients in the sham group (M = 85.8, SD = 60.1).
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min of SLT. Both studies were led by the same laboratory and
run in the same clinical settings, but results were inconsistent.
In line with our results, there was no signiﬁcant effect with the
stimulation protocol in Wang et al, whereas beneﬁcial effects
were reported in Tsai et al where participants received half the
dose of rTMS. Of note is the larger sample size in Tsai et al.’s
RCT and absence of improvement in the control group despite the provision of SLT.
These inconsistent results in chronic aphasia trials indicate
the need for larger RCTs. While for example, contralesional
rTMS for motor recovery has shown evidence of effectiveness in chronic stroke patients in smaller RCTs, a recent well
designed RCT with approximately 200 participants recruited
3 to 12 month after stroke failed to demonstrate a therapeutic
effect on recovery of arm function, and led to revision of the
levels of evidence of rTMS for chronic motor recovery.44,45
These inconsistencies must also draw our attention to
individual factors that could inﬂuence response to rTMS,
such as lesion location and cortical excitability. In the
NORTHSTAR (subacute) trial the positive effect of rTMS on
naming recovery was driven by the patient subgroup whose
lesion had spared Broca’s complex. In NORTHSTAR-CA, all
but two participants had a lesion in Broca’s complex (Table
1). If this lesion location mitigates the response to rTMS on
the contralesional pars triangularis, our chronic sample was at
considerable disadvantage for showing beneﬁts from this
stimulation protocol. Tsai et al did not examine their data
according to lesion location, but they found that the initial
resting motor threshold (RMT i.e. the level of cortical excitability for the FDI of the left hand, which is tested to
calibrate the stimulation intensity before each stimulation
session), was signiﬁcantly associated with the response to
rTMS. We performed this complementary analysis but found
no such signiﬁcant association (see Supplemental material).

Limitations
Patients in the chronic phase had signiﬁcantly larger lesions
than patients in the subacute phase (Figure 3) and a high
percentage had lesions in Broca’s complex. This difference,
which might have masked a potential effect of our protocol in
chronic aphasia, might be related to recruitment procedures.
In the subacute group, every potential patient with speech or
language impairment was approached in the stroke units,
whereas in the chronic group, the study was advertised
through posters and patients or their caregiver had to contact
the study coordinator to express their desire to participate to
the study. This could have introduced a recruitment bias.
Beyond statistical signiﬁcance, it is difﬁcult to state with
certainty the clinical relevance of the results of the language
measures since there is no consensus yet on clinically signiﬁcant changes in most of the tests. This is because they have
typically been constructed to diagnose disorders rather than to
document changes. The absence of parallel versions in most
tests also limits the possibility of ruling out some learning
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effect between two closely spaced administrations. This
limitation applies to our secondary results on changes with
speech therapy, since we did not have a comparison group
without speech therapy. However, we think the possibility of
a practice effect is probably low given the large number of
items in the test we have used, and our results are consistent
with current data from RCTs showing the effectiveness of
SLT in aphasia. Psychometric advances regarding language
measurement tools may be incorporated into future studies on
rTMS for aphasia and include measurements of connected
speech to probe more closely to everyday language skills.
Note also that there is no consensus on the deﬁnition of
exact time windows for acute, subacute, and chronic poststroke phases. Our subacute participants were recruited between 5 and 45 days after stroke, which can be considered an
early period of the subacute phase.

Conclusion and Perspectives
Contralesional 1-Hz rTMS over the right pars triangularis
combined with SLT is a safe add-on therapy for post-stroke
aphasia, independent of the post-stroke phase. The addition of
rTMS to SLT led to signiﬁcant supplemental gains in naming
recovery in the early subacute phase only. While there remains
anecdotal evidence for the efﬁcacy of rTMS in chronic aphasia,
larger trials with longer follow-up periods are needed to identify
potentially smaller and possibly delayed effects on top of effective SLT. Further investigation of this rTMS protocol should
also include patients with different lesion types (e.g.,, hemorrhagic strokes) and determine neuroimaging or other biomarker
factors for its efﬁcacy.
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